Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-019-0690-2
Abstract: Optimization of the salvage regimen is required to improve prognosis in primary refractory or relapsed acute myeloid leukemia (AML). In fit patients, a bridge to allogeneic transplant is the primary purpose of salvage. We tested… read more here.
Keywords: relapsed acute; bridge allogeneic; refractory relapsed; salvage ... See more keywords
Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Haematology"
DOI: 10.1111/bjh.14257
Abstract: Hodgkin lymphoma (HL) affects approximately 1500 new patients annually in the UK (Smith et al, 2011). Most patients are cured with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)-based treatment. Of those who relapse, about 60% achieve durable… read more here.
Keywords: brentuximab vedotin; transplantation; bridge allogeneic; hodgkin lymphoma ... See more keywords
Hypomethylating agent (HMA) treatment as a bridge to allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory acute myeloid leukemia (RR-AML).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7033
Abstract: 7033Background: Outcomes for patients (pts) with RR-AML are poor, with limited treatment options. Salvage HMA therapy has been explored for RR-AML but is often considered palliative. We examined re... read more here.
Keywords: treatment bridge; hypomethylating agent; treatment; hma treatment ... See more keywords